Health Technology

Sector Overview

The Health Technology sector plays a crucial role in the modern healthcare landscape by integrating technology with medical and pharmaceutical advancements. It comprises companies that engage in the research, development, and manufacturing of a wide array of products and services, including medical devices, diagnostic tools, therapeutics, and digital health solutions. This sector is characterized by continuous innovation and is heavily influenced by regulatory frameworks, technological advancements, and the growing demand for personalized medicine and remote healthcare solutions.

Key Metrics

*Weighted by Market Cap Last updated: Jun 21, 2026
Avg P/E Ratio 20.3
Profitable Companies 100%
Avg Growth 51.7%
Avg Dividend Yield 2.82%

Historical Return

Last updated: Jun 15, 2026
1 Year +30.2% +2.8% Div
3 Years Ø +10.3% +2.8% Div
5 Years Ø +6.8% +2.8% Div
1 Year +37.0% +2.8% Div
3 Years Ø +39.1% +2.8% Div
5 Years Ø +11.0% +2.8% Div

Risk & Analysis Metrics

Last updated: Jun 21, 2026

Volatility

23.82% 1 Year
20.03% 3 Years
20.85% 5 Years
19.54% 10 Years

Max Drawdown

-14.32% 1 Year
-16.68% 3 Years
-25.24% 5 Years
-24.54% 10 Years

Sharpe Ratio

1.32 1 Year
0.51 3 Years
0.46 5 Years
0.52 10 Years

Volatility

26.36% 1 Year
24.30% 3 Years
19.93% 5 Years
38.28% 10 Years

Max Drawdown

-49.03% 1 Year
-69.76% 3 Years
-30.10% 5 Years
-98.49% 10 Years

Sharpe Ratio

-1.28 1 Year
-1.16 3 Years
0.68 5 Years
-0.55 10 Years

Return Triangle (Heatmap)

Last updated: Jun 15, 2026
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
2011 8.0% 10.5% 15.6% 12.1% 9.6% 4.8% 6.3% 5.5% 7.6% 7.3% 7.9% 7.0% 6.1% 5.3% 6.9%
2012 13.1% 19.6% 13.5% 10.1% 4.2% 6.1% 5.1% 7.6% 7.2% 7.9% 6.9% 5.9% 5.1% 6.9%
2013 26.6% 13.8% 9.1% 2.1% 4.7% 3.8% 6.8% 6.5% 7.3% 6.3% 5.3% 4.5% 6.4%
2014 2.2% 1.3% -5.0% -0.1% -0.2% 3.8% 3.9% 5.1% 4.2% 3.4% 2.7% 4.9%
2015 0.4% -8.4% -0.9% -0.8% 4.2% 4.1% 5.5% 4.5% 3.5% 2.7% 5.1%
2016 -16.3% -1.5% -1.2% 5.1% 4.9% 6.4% 5.1% 3.9% 3.0% 5.6%
2017 15.9% 7.4% 13.4% 11.0% 11.6% 9.2% 7.1% 5.7% 8.4%
2018 -0.4% 12.2% 9.4% 10.6% 7.9% 5.8% 4.3% 7.5%
2019 26.5% 14.7% 14.5% 10.0% 7.0% 5.1% 8.7%
2020 4.1% 9.0% 5.0% 2.7% 1.3% 5.9%
2021 14.1% 5.5% 2.2% 0.6% 6.3%
2022 -2.4% -3.3% -3.5% 4.5%
2023 -4.2% -4.1% 6.9%
2024 -4.0% 12.8%
2025 32.7%
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
2011 10.3% 13.4% 16.8% 20.7% 18.5% 18.6% 20.6% 16.8% 16.0% 15.1% 14.9% 12.8% 13.4% 14.2% 14.2%
2012 16.6% 20.1% 24.3% 20.6% 20.4% 22.4% 17.8% 16.7% 15.7% 15.4% 13.0% 13.7% 14.5% 14.5%
2013 23.7% 28.4% 21.9% 21.3% 23.6% 18.0% 16.8% 15.5% 15.3% 12.7% 13.4% 14.3% 14.3%
2014 33.3% 21.1% 20.5% 23.5% 16.9% 15.6% 14.4% 14.3% 11.5% 12.4% 13.5% 13.5%
2015 10.0% 14.6% 20.4% 13.1% 12.4% 11.6% 11.8% 9.0% 10.3% 11.7% 11.9%
2016 19.5% 26.0% 14.2% 13.0% 11.9% 12.1% 8.9% 10.3% 11.9% 12.1%
2017 32.9% 11.6% 11.0% 10.0% 10.7% 7.2% 9.1% 11.0% 11.3%
2018 -6.2% 1.4% 3.3% 5.7% 2.7% 5.6% 8.2% 8.9%
2019 9.6% 8.5% 10.0% 5.1% 8.1% 10.8% 11.2%
2020 7.3% 10.2% 3.6% 7.7% 11.0% 11.5%
2021 13.2% 1.8% 7.8% 11.9% 12.3%
2022 -8.5% 5.3% 11.5% 12.1%
2023 21.0% 23.0% 19.9%
2024 25.1% 19.4%
2025 13.9%

Distributions

Last updated: Jun 15, 2026

Profit Margin Distribution

< 0%
0%
1y 3y N/A N/A
0 - 5%
0%
1y 3y N/A N/A
5 - 10%
7%
1y 3y N/A N/A
10 - 15%
2%
1y 3y N/A N/A
15 - 20%
55%
1y 3y N/A N/A
20 - 30%
22%
1y 3y N/A N/A
30 - 40%
15%
1y 3y N/A N/A
> 40%
0%
1y 3y N/A N/A
< 0%
15%
1y 3y N/A N/A
0 - 5%
0%
1y 3y N/A N/A
5 - 10%
15%
1y 3y N/A N/A
10 - 15%
15%
1y 3y N/A N/A
15 - 20%
31%
1y 3y N/A N/A
20 - 30%
8%
1y 3y N/A N/A
30 - 40%
8%
1y 3y N/A N/A
> 40%
8%
1y 3y N/A N/A

P/E Ratio Distribution

< 0
0%
1y 3y N/A N/A
0 - 10
8%
1y 3y N/A N/A
10 - 15
15%
1y 3y N/A N/A
15 - 20
0%
1y 3y N/A N/A
20 - 25
47%
1y 3y N/A N/A
25 - 35
22%
1y 3y N/A N/A
35 - 50
8%
1y 3y N/A N/A
> 50
0%
1y 3y N/A N/A
< 0
15%
1y 3y N/A N/A
0 - 10
23%
1y 3y N/A N/A
10 - 15
8%
1y 3y N/A N/A
15 - 20
0%
1y 3y N/A N/A
20 - 25
15%
1y 3y N/A N/A
25 - 35
8%
1y 3y N/A N/A
35 - 50
23%
1y 3y N/A N/A
> 50
8%
1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation
N/A
Undervalued
> 60%
0%
1y 3y N/A N/A
45 - 60%
0%
1y 3y N/A N/A
30 - 45%
0%
1y 3y N/A N/A
15 - 30%
0%
1y 3y N/A N/A
Fair (&plusmn;15%)
0%
1y 3y N/A N/A
Overvalued
15 - 30%
0%
1y 3y N/A N/A
30 - 45%
0%
1y 3y N/A N/A
45 - 60%
0%
1y 3y N/A N/A
> 60%
0%
1y 3y N/A N/A
Equal Weight Average Undervaluation
N/A
Undervalued
> 60%
0%
1y 3y N/A N/A
45 - 60%
0%
1y 3y N/A N/A
30 - 45%
0%
1y 3y N/A N/A
15 - 30%
0%
1y 3y N/A N/A
Fair (&plusmn;15%)
0%
1y 3y N/A N/A
Overvalued
15 - 30%
0%
1y 3y N/A N/A
30 - 45%
0%
1y 3y N/A N/A
45 - 60%
0%
1y 3y N/A N/A
> 60%
0%
1y 3y N/A N/A

Portfolio Concentration

*by Market Cap Last updated: Jun 15, 2026
91.5% Top 5 Holdings
99.9% Top 10 Holdings
100.0% Top 50 Holdings
100.0% Top 100 Holdings
Top 5 Companies
RHHBF Roche Holding AG
25.0%
AZNCF AstraZeneca Plc
22.0%
NVSEF Novartis AG
21.9%
NONOF Novo Nordisk A/S
14.6%
SNYNF Sanofi
8.0%

Market Cap Size Distribution

Micro Cap
0.0%
1y 3y N/A N/A
Small Cap
0.2%
1y 3y N/A N/A
Mid Cap
0.2%
1y 3y N/A N/A
Large Cap
30.7%
1y 3y N/A N/A
Mega Cap
68.9%
1y 3y N/A N/A
Micro: < $300M Small: $300Mā€“$2B Mid: $2Bā€“$10B Large: $10Bā€“$200B Mega: > $200B
Micro Cap
15.4%
1y 3y N/A N/A
Small Cap
15.4%
1y 3y N/A N/A
Mid Cap
7.7%
1y 3y N/A N/A
Large Cap
38.5%
1y 3y N/A N/A
Mega Cap
23.1%
1y 3y N/A N/A
Micro: < $300M Small: $300Mā€“$2B Mid: $2Bā€“$10B Large: $10Bā€“$200B Mega: > $200B

Latest News

View all news →
about 1 month ago • GlobeNewsWire

AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT

New York, NY, May 20, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the ā€œCompanyā€) (Nasdaq: AFJK) today announced that on May 19, 2026...
about 1 month ago • GlobeNewsWire

Haoxi Health Technology Limited Announces 1-For-128 Reverse Share Split

BEIJING, May 19, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; ā€œweā€ or the ā€œCompanyā€), today announced that it will effect...
about 1 month ago • seekingalpha.com

BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript

Industries

5 total

Average metrics of all companies in sector Last updated: Jun 21, 2026

Compare to
Market
Market Cap The average market value of companies in this sector. $184B
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 2.82 %
Beta Indicates the relationship between the price performance of a share and the market. 0.32
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 20.31
Negative P/E Ratio A negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything. -
Profitable Companies 100%
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 13.33
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 3.29
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company. 5.52
Compare to
Market
Enterprise Value to EBIT Enterprise Value divided by EBIT. 15.98
Enterprise Value to Revenue Enterprise value divided by revenue. 3.78
Total Debt to Enterprise Value Total debt divided by enterprise value. 0.18
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.84
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 21.10%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +51.7%
Return on Equity Equity divided by market cap. 38.74%
Return on Assets Indicates a company's profitability in relation to its total assets. 13.94%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 27.16%

Stock Screener

Select filters to narrow down the 29 companies below

29 companies
$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%
Market Cap
Dividends Ratio of dividends in the last 12 months to current share price
P/E Ratio
Revenue Revenue of the last quarter YoY Change
Net income Net income of the last quarter YoY Change
Profit margin Profit margin of the last quarter

Roche Holding AG

RHHVF

Roche Holding AG

RHHVF
Market Cap $327.35B
Dividends 3.1%
P/E Ratio 19.8
Revenue $29.7B -6.1%
Net Income $5.47B +171.1%
Profit Margin +18.4%
View Stock

Roche Holding AG - ADR

RHHBY

Roche Holding AG - ADR

RHHBY
Market Cap $327.35B
Dividends 3.1%
P/E Ratio 19.8
Revenue $29.7B -6.1%
Net Income $5.47B +171.1%
Profit Margin +18.4%
View Stock

Roche Holding AG

RHHBF

Roche Holding AG

RHHBF
Market Cap $327.35B
Dividends 3.1%
P/E Ratio 19.8
Revenue $29.7B -6.1%
Net Income $5.47B +171.1%
Profit Margin +18.4%
View Stock

Astrazeneca plc - ADR

AZN

Astrazeneca plc - ADR

AZN
Market Cap $294.4B
Dividends 1.8%
P/E Ratio 26.0
Revenue $15.5B +4.1%
Net Income $2.33B +55.1%
Profit Margin +15.0%
View Stock

AstraZeneca PLC

AZNCF

AstraZeneca PLC

AZNCF
Market Cap $294.4B
Dividends 1.8%
P/E Ratio 26.0
Revenue $15.5B +4.1%
Net Income $2.33B +55.1%
Profit Margin +15.0%
View Stock

Novartis AG - ADR

NVS

Novartis AG - ADR

NVS
Market Cap $280.64B
Dividends 3.1%
P/E Ratio 20.8
Revenue $12.9B -5.6%
Net Income $3.09B -15.5%
Profit Margin +24.1%
View Stock

Novartis AG

NVSEF

Novartis AG

NVSEF
Market Cap $280.64B
Dividends 3.1%
P/E Ratio 20.8
Revenue $12.9B -5.6%
Net Income $3.09B -15.5%
Profit Margin +24.1%
View Stock

Novo Nordisk A/S Class B

NONOF

Novo Nordisk A/S Class B

NONOF
Market Cap $192.8B
Dividends 4.0%
P/E Ratio 10.7
Revenue $96.8B +24.0%
Net Income $48.6B +67.2%
Profit Margin +50.2%
View Stock

Sanofi - ADR

SNY

Sanofi - ADR

SNY
Market Cap $106.91B
Dividends 5.6%
P/E Ratio 8.6
Revenue $11.2B +6.0%
Net Income $1.61B -13.8%
Profit Margin +14.4%
View Stock

Sanofi

SNYNF

Sanofi

SNYNF
Market Cap $106.91B
Dividends 5.6%
P/E Ratio 8.6
Revenue $11.2B +6.0%
Net Income $1.61B -13.8%
Profit Margin +14.4%
View Stock

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

BDXA

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

BDXA
Market Cap $55.91B
Dividends 2.6%
P/E Ratio 36.5
Revenue $4.71B -10.6%
Net Income -$311M -201.0%
Profit Margin -6.6%
View Stock

Alcon Inc. - Registered Shares

ALC

Alcon Inc. - Registered Shares

ALC
Market Cap $31.53B
Dividends 0.6%
P/E Ratio 39.0
Revenue $2.65B +7.3%
Net Income $185M -47.0%
Profit Margin +7.0%
Employees 20K
View Stock

Straumann Holding AG

SAUHF

Straumann Holding AG

SAUHF
Market Cap $21.07B
Dividends 1.0%
P/E Ratio 46.5
Revenue $1.26B +2.2%
Net Income $120M -24.1%
Profit Margin +9.5%
View Stock

Elekta AB Class B

EKTAF

Elekta AB Class B

EKTAF
Market Cap $1.85B
Dividends 4.9%
P/E Ratio -35.9
Revenue $4.73B -8.2%
Net Income -$860M +122.9%
Profit Margin -18.2%
View Stock

PT Kalbe Farma Tbk

PTKFF

PT Kalbe Farma Tbk

PTKFF
Market Cap $1.82B
Dividends 2.9%
P/E Ratio 8.8
Revenue $9.7T +9.7%
Net Income $1.03T -4.2%
Profit Margin +10.6%
View Stock

Brainsway Ltd

BRSYF

Brainsway Ltd

BRSYF
Market Cap $675.68M
Dividends 0.0%
P/E Ratio 64.6
Revenue $15.5M +34.6%
Net Income $2.29M +106.9%
Profit Margin +14.7%
View Stock

Brainsway Ltd - ADR

BWAY

Brainsway Ltd - ADR

BWAY
Market Cap $675.68M
Dividends 0.0%
P/E Ratio 64.6
Revenue $15.5M +34.6%
Net Income $2.29M +106.9%
Profit Margin +14.7%
View Stock

Cipher Pharmaceuticals Inc.

CPHRF

Cipher Pharmaceuticals Inc.

CPHRF
Market Cap $289.71M
Dividends 0.0%
P/E Ratio 9.5
Revenue $12.3M +2.6%
Net Income $6.08M +131.6%
Profit Margin +49.3%
View Stock

Abattis Bioceuticals Corp.

ATTBF

Abattis Bioceuticals Corp.

ATTBF
Market Cap $14.33K
Dividends 0.0%
P/E Ratio -0.0
Revenue $226k
Net Income -$907k
Profit Margin -400.9%
View Stock

Itamar Medical Ltd - ADR

ITMR

Itamar Medical Ltd - ADR

ITMR
Market Cap $0
Dividends 0.0%
P/E Ratio -39.1
Revenue $13.6M
Net Income -$7.98M
Profit Margin -58.8%
View Stock